Publications by authors named "Mark D Minden"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

74,595

Total Likes

1,220

Extended Reach

197,698

Social Features

49
V
Very long chain fatty acid metabolism is required in acute myeloid leukemia.
Matthew Tcheng, Alessia Roma, Nawaz Ahmed, Richard W Smith, Preethi Jayanth, Mark D Minden, Aaron D Schimmer, David A Hess, Kristin Hope, Kevin A Rea

Blood· June 2021

Videos about Article: user user

2 47 5 22

View All Article and Social Media Activity
C
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.
Travis J Fleming, Mateusz Antoszewski, Sander Lambo, Michael C Gundry, Riccardo Piussi, Mark D Minden

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.
Cristiana O'Brien, Nirvana Nursimulu, Anit Tyagi, Rachel Culp-Hill, Andrea Arruda, Mark D Minden

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.
Guillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, Severine Cathelin, Lisa Wang, Mark D Minden

Lancet Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Immune Checkpoint Blockade is Enhanced in the Presence of Hematopoietic TET2 Inactivation.
Vincent Rondeau, Suraj Bansal, Marco M Buttigieg, Andy G X Zeng, Darryl Y Chan, Mark D Minden

Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.
Tianyi Ling, Cristiana O'Brien, Jonathan St-Germain, Vincent Rondeau, Mary Shi, Mark D Minden

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Risk Factors and Outcome for CNS Involvement in AML.
Jack T Seki, Georgina S Daher-Reyes, Eshetu G Atenafu, Jad Sibai, Aniket Bankar, Mark D Minden

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?
Akhil Rajendra, Elliot Smith, Eshetu G Atenafu, Aniket Bankar, Steven Chan, Mark D Minden

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue Prior to the Initial Hematoxylin-Eosin Section Demonstrates Value as an Alternative Source of DNA for Molecular Testing.
Peter Sabatini, Robert Ta, Melanie Peralta, Melanie Anderson, Shehnaz Khan, Mark David Minden

Arch Pathol Lab Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models.
Xinyue Zhou, Steven Moreira, Cecilia Restelli, Hong Wang, Soheil Jahangiri, Mark D Minden

Sci Transl Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.
Akhil Rajendra, Elliot Smith, Maria Agustina Perusini, Kenny Tang, Eshetu G Atenafu, Mark D Minden

Blood Cancer J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell Transcriptional Atlas of Human Hematopoiesis Reveals Genetic and Hierarchy-Based Determinants of Aberrant AML Differentiation.
Andy G X Zeng, Ilaria Iacobucci, Sayyam Shah, Amanda Mitchell, Gordon Wong, Mark D Minden

Blood Cancer Discov· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma.
Davidson Zhao, Noémie Lang, Ting Liu, Victoria Shelton, Juan Rangel-Patiño, Mark D Minden

JCO Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.
Tracy Murphy, Boyang Zhang, Tong Zhang, Ian King, Jose-Mario Capo-Chichi, Mark D Minden

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes.
Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek, Bin Yuan, Yu-An Kuo, Mark D Minden

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells.
Joana L Araújo, Elvin Wagenblast, Veronique Voisin, Jessica McLeod, Olga I Gan, Mark D Minden

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dietary Modulation of Fatty Acid Oxidation Imparts Stem Cell Protection in Bone Marrow.
Nawaz Ahmed, Sarah Walker, Alessia Roma, Mark D Minden, Paul A Spagnuolo

Nutr Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity.
Enoch Tin, Sergio Rutella, Ismat Khatri, Yoosu Na, Yongran Yan, Mark D Minden

Blood Cancer Discov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study.
Monzr M Al Malki, Mark D Minden, Elizabeth Shima Rich, Jason E Hill, Stanley C Gill

Leuk Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant cooperates with or to drive distinct myeloid diseases and molecular outcomes.
Takashi Sakamoto, Julie Leca, Xin Zhang, Cem Meydan, Jonathan Foox, Mark D Minden

Proc Natl Acad Sci U S A· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing.
Yael Morgenstern, JongBok Lee, Yoosu Na, Brandon Y Lieng, Nicholas S Ly, Mark D Minden

Haematologica· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapy.
James T Hagen, McLane M Montgomery, Raphael T Aruleba, Brett R Chrest, Polina Krassovskaia, Mark D Minden

Sci Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy.
Enoch Tin, Ismat Khatri, Karen Fang, Yoosu Na, Michele Nawata, Mark D Minden

J Immunother Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study.
Emmanuel Gyan, Mark D Minden, Kohmei Kubo, Alessandro Rambaldi, Gunnar Juliusson

Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD.
Jongbok Lee, Hyeonjeong Kang, Branson Chen, Yoosu Na, Ismat Khatri, Mark D Minden

J Exp Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.
Travis J Fleming, Mateusz Antoszewski, Sander Lambo, Michael C Gundry, Riccardo Piussi, Mark D Minden

bioRxiv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis